PTEN loss is a predictive marker for HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies

Autor:	Tekesin, K., Akar, E., Emingunes, M., Bayrak, S., Tulin Ozturk, Altinay, S., Tural, D.
Zdroj:	Scopus-Elsevier
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::4480b00b2d39400edee07191e55ed852 http://www.scopus.com/inward/record.url?eid=2-s2.0-85074998597&partnerID=MN8TOARS Zobrazit plný text záznamu